Disposition of levetiracetam in healthy adult horses
Metadata Field | Value | Language |
---|---|---|
dc.contributor.advisor | Stewart, Allison | |
dc.contributor.advisor | Boothe, Dawn | |
dc.contributor.advisor | Ravis, William R. | |
dc.contributor.advisor | Duran, Sue | |
dc.contributor.advisor | Wooldridge, Anne | |
dc.contributor.advisor | Robyn, Wilborn | |
dc.contributor.author | Cesar, Fernanda | |
dc.date.accessioned | 2014-07-11T15:14:47Z | |
dc.date.available | 2014-07-11T15:14:47Z | |
dc.date.issued | 2014-07-11 | |
dc.identifier.uri | http://hdl.handle.net/10415/4258 | |
dc.description.abstract | Nine horses received 20 mg/kg of intravenous LEV (LEVIV), 30 mg/kg of intragastric, immediate release LEV (LEVIR) and extended release (LEVER), in a 3-way randomized crossover design. Serum samples were collected over 48 hours, and LEV concentrations determined by immunoassay. Mean SEM peak concentrations for LEVIR and LEVER were 50.72 3.53 and 53.58 5.31 g/mL, respectively. The mean y-intercept for IV administration was 64.54 8.33 g/mL. The terminal half-life was 6.38 1.97, 7.07 1.93 and 6.22 1.35 hours for LEVIR, LEVER and LEVIV, respectively. Volume of distribution at steady state was 0.63 0.02 L/kg. Total body clearance after IV administration was 1.24 0.10 ml/kg/min. Bioavailability was excellent. Based on this study, a recommended dosing regimen of intravenous or oral LEV, of 32 mg/kg every 12 hours is likely to achieve and maintain therapeutic range with optimal kinetics throughout dosing interval. | en_US |
dc.rights | EMBARGO_NOT_AUBURN | en_US |
dc.subject | Biomedical Sciences | en_US |
dc.title | Disposition of levetiracetam in healthy adult horses | en_US |
dc.type | thesis | en_US |
dc.embargo.length | NO_RESTRICTION | en_US |
dc.embargo.status | NOT_EMBARGOED | en_US |